The exploratory study to evaluate the association between efficacy of bevacizumab combination therapy and pretreatment plasma vascular endothelial growth factor-D levels in metastatic colorectal cancer (GI-SCREEN-CRC-Ukit additional study 01)

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms GI-SCREEN-CRC-Ukit additional study 01

Most Recent Events

20 Jan 2024 Results of pooled analysis from pooled analysis of SCRUM-Japan studies, analyzing Efficacy of biomarker-matched therapy in advanced gastrointestinal cancers, presented at the 2024 Gastrointestinal Cancers Symposium
05 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight